tradingkey.logo

tradingkey.logo
怜玢


Alkermes Plc

ALKS
りォッチリストに远加
38.560USD
+0.270+0.71%
取匕時間 ET15分遅れの株䟡
6.39B時䟡総額
41.47盎近12ヶ月PER


詳现情報 Alkermes Plc 䌁業名

Alkermes plc is Ireland-based biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. It has a manufacturing facility in Wilmington, Ohio.

Alkermes Plcの䌁業情報


䌁業コヌドALKS
䌚瀟名Alkermes Plc
䞊堎日Jul 16, 1991
最高経営責任者「CEO」Pops (Richard F)
埓業員数1800
蚌刞皮類Ordinary Share
決算期末Jul 16
本瀟所圚地Connaught House
郜垂DUBLIN
蚌刞取匕所NASDAQ OMX - NASDAQ BASIC
囜Ireland
郵䟿番号D04 C5Y6
電話番号35317728000
りェブサむトhttps://www.alkermes.com/
䌁業コヌドALKS
䞊堎日Jul 16, 1991
最高経営責任者「CEO」Pops (Richard F)

Alkermes Plcの経営陣


䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Mr. Richard F. Pops
Mr. Richard F. Pops
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
1.38M
--
Mr. David Joseph Gaffin
Mr. David Joseph Gaffin
Executive Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary
Executive Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary
231.56K
-0.88%
Mr. Shane M. Cooke
Mr. Shane M. Cooke
Independent Director
Independent Director
103.74K
--
Dr. Craig C. Hopkinson, M.D.
Dr. Craig C. Hopkinson, M.D.
Executive Vice President, Research and Development and Chief Medical Officer
Executive Vice President, Research and Development and Chief Medical Officer
81.39K
-4.91%
Mr. Frank Anders (Andy) Wilson, CPA
Mr. Frank Anders (Andy) Wilson, CPA
Lead Independent Director
Lead Independent Director
31.08K
--
Dr. Cato T. Laurencin, M.D., Ph.D.
Dr. Cato T. Laurencin, M.D., Ph.D.
Independent Director
Independent Director
29.10K
--
Dr. Christopher I. Wright, M.D., Ph.D.
Dr. Christopher I. Wright, M.D., Ph.D.
Independent Director
Independent Director
23.01K
--
Ms. Nancy S. Lurker
Ms. Nancy S. Lurker
Independent Director
Independent Director
13.55K
+21.03%
Dr. Nancy L. Snyderman, M.D.
Dr. Nancy L. Snyderman, M.D.
Independent Director
Independent Director
--
--
Mr. C. Todd Nichols
Mr. C. Todd Nichols
Senior Vice President, Chief Commercial Officer
Senior Vice President, Chief Commercial Officer
--
--
詳现を芋る
䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Mr. Richard F. Pops
Mr. Richard F. Pops
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
1.38M
--
Mr. David Joseph Gaffin
Mr. David Joseph Gaffin
Executive Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary
Executive Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary
231.56K
-0.88%
Mr. Shane M. Cooke
Mr. Shane M. Cooke
Independent Director
Independent Director
103.74K
--
Dr. Craig C. Hopkinson, M.D.
Dr. Craig C. Hopkinson, M.D.
Executive Vice President, Research and Development and Chief Medical Officer
Executive Vice President, Research and Development and Chief Medical Officer
81.39K
-4.91%
Mr. Frank Anders (Andy) Wilson, CPA
Mr. Frank Anders (Andy) Wilson, CPA
Lead Independent Director
Lead Independent Director
31.08K
--
Dr. Cato T. Laurencin, M.D., Ph.D.
Dr. Cato T. Laurencin, M.D., Ph.D.
Independent Director
Independent Director
29.10K
--

収益内蚳

通貚: USD曎新時刻: Mon, Apr 6
通貚: USD曎新時刻: Mon, Apr 6
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
事業別USD
䌚瀟名
収益
比率
VIVITROL
467.91M
31.70%
ARISTADA
370.04M
25.07%
LYBALVI
346.69M
23.49%
Royalty Revenue - VUMERITY
113.93M
7.72%
Royalty-INVEGA SUSTENNA/XEPLION & INVEGA TRINZA/TREVICTA
109.57M
7.42%
他の
67.75M
4.59%
地域別USD
䌚瀟名
収益
比率
United States
1.37B
93.01%
Rest of the World
102.36M
6.94%
Ireland
754.00K
0.05%
事業別
地域別
事業別USD
䌚瀟名
収益
比率
VIVITROL
467.91M
31.70%
ARISTADA
370.04M
25.07%
LYBALVI
346.69M
23.49%
Royalty Revenue - VUMERITY
113.93M
7.72%
Royalty-INVEGA SUSTENNA/XEPLION & INVEGA TRINZA/TREVICTA
109.57M
7.42%
他の
67.75M
4.59%

株䞻

曎新時刻: Thu, May 7
曎新時刻: Thu, May 7
株䞻統蚈
皮類
株䞻統蚈
株䞻統蚈
比率
BlackRock Institutional Trust Company, N.A.
14.44%
Baker Bros. Advisors LP
6.01%
Vanguard Portfolio Management, LLC
5.71%
State Street Investment Management (US)
5.68%
T. Rowe Price Associates, Inc.
5.28%
他の
62.88%
株䞻統蚈
株䞻統蚈
比率
BlackRock Institutional Trust Company, N.A.
14.44%
Baker Bros. Advisors LP
6.01%
Vanguard Portfolio Management, LLC
5.71%
State Street Investment Management (US)
5.68%
T. Rowe Price Associates, Inc.
5.28%
他の
62.88%
皮類
株䞻統蚈
比率
Investment Advisor
53.52%
Investment Advisor/Hedge Fund
29.75%
Hedge Fund
19.22%
Research Firm
2.49%
Pension Fund
2.14%
Individual Investor
1.41%
Sovereign Wealth Fund
1.17%
Bank and Trust
0.48%
Private Equity
0.42%

機関投資家保有株


曎新時刻: Wed, Apr 1
曎新時刻: Wed, Apr 1
報告期間
機関投資家数
保有株匏数
比率
倉動額
2026Q1
783
182.39M
109.43%
-12.00M
2025Q4
744
175.23M
117.54%
-23.12K
2025Q3
767
175.30M
122.16%
+2.11M
2025Q2
769
173.38M
125.62%
-4.15M
2025Q1
759
177.46M
124.05%
-27.05M
2024Q4
734
172.08M
130.58%
-12.03M
2024Q3
705
184.36M
134.23%
-884.11K
2024Q2
687
185.17M
126.42%
+3.87M
2024Q1
659
181.61M
124.10%
-28.36M
2023Q4
633
182.01M
111.83%
+12.84M
詳现を芋る

株䞻動向


䌚瀟名
保有株匏数
比率
倉動額
倉動率
日付
BlackRock Institutional Trust Company, N.A.
24.07M
14.44%
+417.41K
+1.76%
Dec 31, 2025
Baker Bros. Advisors LP
10.01M
6.01%
+1.92M
+23.74%
Dec 31, 2025
State Street Investment Management (US)
9.47M
5.68%
+932.51K
+10.92%
Dec 31, 2025
T. Rowe Price Associates, Inc.
8.80M
5.28%
-1.25M
-12.41%
Dec 31, 2025
Renaissance Technologies LLC
6.67M
4%
+375.50K
+5.97%
Dec 31, 2025
American Century Investment Management, Inc.
5.96M
3.57%
+1.56M
+35.46%
Dec 31, 2025
JP Morgan Asset Management
4.83M
2.9%
+1.21M
+33.37%
Dec 31, 2025
Dimensional Fund Advisors, L.P.
4.41M
2.65%
+714.79K
+19.33%
Dec 31, 2025
詳现を芋る

関連ETF


曎新時刻: Sat, Dec 6
曎新時刻: Sat, Dec 6
銘柄名
比率
AdvisorShares Psychedelics ETF
7.31%
iShares Neuroscience and Healthcare ETF
3.82%
First Trust NYSE Arca Biotechnology Index Fund
3.3%
Invesco S&P SmallCap Health Care ETF
3.1%
ALPS Medical Breakthroughs ETF
2.07%
Knowledge Leaders Developed World ETF
1.69%
Langar Global HealthTech ETF
1.44%
State Street SPDR S&P Biotech ETF
1.35%
Abacus FCF International Leaders ETF
1.34%
Invesco S&P SmallCap Quality ETF
1.32%
詳现を芋る
AdvisorShares Psychedelics ETF
比率7.31%
iShares Neuroscience and Healthcare ETF
比率3.82%
First Trust NYSE Arca Biotechnology Index Fund
比率3.3%
Invesco S&P SmallCap Health Care ETF
比率3.1%
ALPS Medical Breakthroughs ETF
比率2.07%
Knowledge Leaders Developed World ETF
比率1.69%
Langar Global HealthTech ETF
比率1.44%
State Street SPDR S&P Biotech ETF
比率1.35%
Abacus FCF International Leaders ETF
比率1.34%
Invesco S&P SmallCap Quality ETF
比率1.32%

配圓金


過去5幎間の配圓金総支払額は 0.00 米ドルである。
日付
配圓金
暩利確定日
支払日
配圓萜ち日
デヌタなし

株匏分割


日付
配圓萜ち日
皮類
比率
デヌタなし
日付
配圓萜ち日
皮類
比率
デヌタなし
KeyAI
î™